People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Heron Therapeutics, Inc. /De/ | — | Biotechnology | Series C | $117.2M | $382.0M | 2009 |
| CymaBay Therapeutics, Inc. | — | Biotechnology | Series B | $90.6M | $12.9M | 2008 |
| Metabolic Solutions Development Co Llc | — | Pharmaceuticals | Series B | $50.1M | $6.8M | 2012 |
| Cirius Therapeutics, Inc. | — | Biotechnology | Series B | $49.6M | $3.3M | 2017 |
| Octeta Therapeutics, LLC | — | Biotechnology | Series B | $16.4M | $650.9M | 2016 |
Robert Zerbe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Zerbe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Olesnavage | 2 | 4 |
| Michael Jandernoa | 2 | 2 |
| CRAIG JOHNSON | 1 | 16 |
| BRADLEY BOLZON | 1 | 10 |
| Kurt Von Emster | 1 | 6 |
| Anthony Evnin | 1 | 6 |
| Carl Goldfischer | 1 | 5 |
| Robert Beardsley | 1 | 5 |
| William U. Parfet | 1 | 5 |
| Robert A. Beardsley | 1 | 4 |
| Nilesh Kumar | 1 | 4 |
| Paul Goddard | 1 | 4 |
| Jim Schultz | 1 | 3 |
| Daniel Estes | 1 | 3 |
| Elaine Sun | 1 | 3 |
| Kevin Kotler | 1 | 3 |
| John Barr | 1 | 3 |
| Gerald Callahan | 1 | 3 |
| Edward E. Penhoet, Ph.D. | 1 | 3 |
| Kevin Tang | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.